Etoricoxib vs Piroxicam in Rheumatoid Arthritis

Safety Considerations

Both etoricoxib and piroxicam carry cardiovascular risks, with the risk being proportional to COX-2 selectivity and the patient's underlying cardiovascular risk 1
NSAIDs, including both medications, should be used at the minimum effective dose for the shortest time possible after evaluation of gastrointestinal, renal, and cardiovascular risks 2
For patients with a history of symptomatic or complicated upper GI ulcer, a COX-2 selective inhibitor like etoricoxib is strongly recommended over nonselective NSAIDs like piroxicam 3

Etoricoxib should be used at the lowest effective dose for the shortest possible duration, typically 2-4 weeks for active treatment phase 1
For chronic conditions like RA, treatment response should be evaluated at 2-4 weeks after initiation, and if response is sufficient, continued treatment should be re-evaluated at 12 weeks 1

For patients aged ≥75 years, topical NSAIDs are strongly recommended over oral NSAIDs (including both etoricoxib and piroxicam) due to reduced gastrointestinal risk 3
Patients taking low-dose aspirin for cardioprotection should be cautious with NSAID use due to potential interactions that may reduce aspirin's cardioprotective effects 3
Neither etoricoxib nor piroxicam should be used in patients with chronic kidney disease stage IV or V (eGFR <30 ml/min) 3
For patients with or at risk for cardiovascular disease, a stepped-care approach to pain management is recommended, starting with acetaminophen, ASA, tramadol, or narcotic analgesics before considering NSAIDs 1

NSAIDs like etoricoxib and piroxicam are generally used as symptomatic therapy in RA, while disease-modifying antirheumatic drugs (DMARDs) like methotrexate remain the cornerstone of treatment 4, 5, 6
Systemic glucocorticoids may be used as temporary (<6 months) adjunctive treatment at the lowest dose necessary 2
Intra-articular glucocorticoid injections should be considered for the relief of local symptoms of inflammation 2
When choosing between etoricoxib and piroxicam, consider the patient's individual risk factors for gastrointestinal and cardiovascular adverse events 1, 3

Regular monitoring of blood pressure, renal function, and liver function is recommended for patients on long-term NSAID therapy 1
Monitor for common side effects of etoricoxib, which include gastrointestinal disturbances, hypertension, and edema 1
For patients with sustained response at 12 weeks, consider switching to on-demand treatment or dose tapering 1